Valuation: ProPhase Labs, Inc.

Market Cap 2L 2L 2L 1L 3L 1.83Cr 3L 18.78L 7L 93.22L 7L 7L 3.01Cr P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 87.19L 76.02L 71.6L 65.21L 1.22Cr 84Cr 1.22Cr 8.57Cr 3.3Cr 43Cr 3.28Cr 3.2Cr 137.31Cr EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
92.7%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day-13.79%
1 week+639.64%
Current month+492.42%
1 month+360.95%
3 months+66.67%
6 months+43.51%
Current year-72.07%
1 week 0.01
Extreme 0.01225
0.14
1 month 0.01
Extreme 0.01225
0.14
Current year 0.01
Extreme 0.01225
0.47
1 year 0.01
Extreme 0.01225
6.66
3 years 0.01
Extreme 0.01225
74.8
5 years 0.01
Extreme 0.01225
152.5
10 years 0.01
Extreme 0.01225
160.4
Manager TitleAgeSince
Chief Executive Officer 67 19/06/2009
Director of Finance/CFO 66 06/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 19/06/2009
Director/Board Member 70 01/06/2009
Director/Board Member 56 20/06/2025
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/25 Free

Chief Executive Officer

5,00,000 1.2036%
17/02/25 Free

Chief Operating Officer

5,00,000 1.6737%
14/02/25 Free

Director

1,00,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-13.79%+639.64%-96.78%-99.71% 2L
+0.34%+8.44%+106.84%+683.76% 5.32TCr
+0.09%+1.80%+15.09%+56.47% 2.6TCr
+1.20%+2.47%-13.20%-35.23% 675.85Cr
-4.38%-3.74%-3.93%+166.19% 598.1Cr
+1.24%+0.60%+10.57%+59.01% 330.26Cr
-3.23%+9.01%-24.62%+2,580.27% 301.51Cr
-2.51%+5.43%+131.07%+59.10% 255.79Cr
+17.67%+2.71%+37.89%+47.22% 225.01Cr
+2.68%+11.00%-6.29%-54.07% 190.85Cr
Average -0.11%+5.85%+15.67%+346.30% 1.05TCr
Weighted average by Cap. +0.14%+8.12%+60.34%+445.22%

Financials

2024 2025
Net sales 67.7L 59.03L 55.59L 50.63L 94.93L 65Cr 95.04L 6.66Cr 2.57Cr 33Cr 2.54Cr 2.49Cr 106.61Cr 43.45L 37.88L 35.68L 32.49L 60.92L 42Cr 61L 4.27Cr 1.65Cr 21Cr 1.63Cr 1.6Cr 68Cr
Net income -5.34Cr -4.65Cr -4.38Cr -3.99Cr -7.48Cr -511.24Cr -7.49Cr -52Cr -20Cr -260.43Cr -20Cr -20Cr -840.38Cr -1.47Cr -1.29Cr -1.21Cr -1.1Cr -2.07Cr -141.24Cr -2.07Cr -14Cr -5.59Cr -72Cr -5.54Cr -5.42Cr -232.17Cr
Net Debt 2.39Cr 2.08Cr 1.96Cr 1.79Cr 3.35Cr 228.92Cr 3.35Cr 23Cr 9.06Cr 116.61Cr 8.98Cr 8.78Cr 376.3Cr 85.28L 74.36L 70.03L 63.78L 1.2Cr 82Cr 1.2Cr 8.39Cr 3.23Cr 42Cr 3.2Cr 3.13Cr 134.3Cr
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
18/26/18 $0.0123 -17.09% 1,05,016
17/26/17 $0.0148 +4.94% 49,274
16/26/16 $0.0141 -6.13% 46,333
15/26/15 $0.0150 -1.96% 1,278

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!